NCT07122414 - A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

October 10, 2027

Study Completion Date

October 10, 2028

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG

FL115

FL115 single agent dose escalation,

DRUG

FL115+BCG

FL115 in combination with BCG

Trial Locations (12)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

100191

RECRUITING

Peking University Third Hospital, Beijing

200000

RECRUITING

Fudan University Cancer Hospital, Shanghai

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

215004

RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

266000

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

300211

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

350005

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

410030

RECRUITING

Hunan Cancer Hospital, Changsha

610072

RECRUITING

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors

lead

Suzhou Forlong Biotechnology Co.,Ltd,

INDUSTRY